Kind Pharmaceutical 将在 2024 年 10 月的 ASN 肾脏周上展示关于透析依赖性慢性肾病贫血的 AND017 2 期临床试验结果。 Kind Pharmaceutical to present AND017 Phase 2 clinical trial findings on anemia in dialysis-dependent chronic kidney disease at ASN Kidney Week, October 2024.

Kind Pharmaceutical 将于 2024 年 10 月 24 日至 27 日在圣地亚哥举行的 ASN 肾脏周上展示其治疗透析依赖性慢性肾病贫血的 AND017 2 期临床试验结果。 Kind Pharmaceutical will present its AND017 Phase 2 clinical trial findings on treating anemia in dialysis-dependent chronic kidney disease at the ASN Kidney Week in San Diego from October 24-27, 2024. 该公司还将展示与非透析依赖慢性肾脏疾病有关的第一阶段和第二阶段成果的三张海报。 The company will also showcase three posters on Phase 1 and Phase 2 results related to non-dialysis-dependent chronic kidney disease. AND017是一种先锋性血红蛋白提升剂,旨在解决与若干医疗条件有关的贫血问题。 AND017 is a pioneering hemoglobin elevating agent aimed at addressing anemia linked to several medical conditions.